Bauer Jake 4
4 · Enliven Therapeutics, Inc. · Filed Feb 27, 2023
Insider Transaction Report
Form 4
Bauer Jake
Director
Transactions
- Award
Stock Option
2023-02-23+17,706→ 17,706 totalExercise: $2.48Exp: 2032-08-12→ Common Stock (17,706 underlying) - Award
Common Stock
2023-02-23+87,372→ 87,372 total
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of the Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."
- [F2]Shares subject to the option vest in 24 equal monthly installments beginning on September 24, 2022.